Trial Profile

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Patidegib (Primary)
Indications Basal cell cancer; Basal cell nevus syndrome
Focus Adverse reactions; Registrational
Acronyms PATIDEGIB
Sponsors PellePharm; Sol-Gel Technologies

Most Recent Events

01 Sep 2021 Status changed from recruiting to discontinued early due to low blinded event rate and this study termination is not related to safety of the drug Patidegib Topical Gel, 2%.
09 Aug 2021 This trial has been discontinued in Denmark, as per European Clinical Trials Database record
22 Jun 2021 This trial has been discontinued in Netherlands, as per European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com